Palatin Technology' Bremelonotide在治疗糖尿病肾脏疾病、增加库存方面显示出希望。 Palatin Technologies' Bremelanotide shows promise in treating diabetic kidney disease, boosting stock.

Palatin Technology报告Bremelanotide在治疗2型糖尿病肾病(慢性肾病的一个主要原因)的第二阶段b试验取得积极结果。 Palatin Technologies reported positive Phase IIb trial results for Bremelanotide in treating Type 2 diabetic nephropathy, a leading cause of chronic kidney disease. 研究表明,71%的病人尿中蛋白质减少了30%,71%的病人肾功能得到改善。 The study showed 71% of patients achieved a 30% reduction in protein in urine and 71% had improved kidney function. 公司股价上升4.37%至0.78美元,取得积极成果。 The company's stock rose 4.37% to $0.78 on the positive results.